Deceptive drug kratom leaves Alabama users battling severe addiction, withdrawal
BIRMINGHAM, Alabama (WVTM) - Kratom, a natural supplement derived from a tree native to Southeast Asia, is getting a lot of attention in the U.S. because it's highly addictive, and many people who think it's perfectly safe are finding themselves unable to stop using it. Alabama is one of only a few states where it's illegal, but it is still a problem here.
Angela Edwards is living and working at the Lovelady Center in Birmingham. She's dealing with addiction, and most recently, her drug of choice was kratom.
'Every day. I was taking it every day. All day,' she said.
Experts call it a deceptive drug, because it's plant-based and all natural, there's the belief it must be safe. It's even marketed as an alternative to alcohol.
Frank Long, with the Lovelady Center said, 'It's an opioid-like effect. You know, some people describe it like a warm hug. You know, it's kind of that feeling of peacefulness and that everything's OK. Or maybe you just don't care about anything. So, it kind of makes you forget your worries.'
Long said it's highly addictive and users quickly develop a tolerance to it, so they're compelled to use more and more to get the same effect. And when they try to quit, withdrawal symptoms are reportedly worse than those associated with coming off heroin.
'I was on kratom for about two years, if not longer,' Edwards said. 'And at the time when I was on kratom, you know, it was good when I was on it, but when I was coming off kratom, I thought I was going to die, you know, the withdrawals were worse than any kind of withdrawals that I've ever had.'
An estimated 1.7 million Americans 12 and older used kratom in 2021, according to the Substance Abuse and Mental Health Services Administration's National Survey on Drug Use and Health.
In July, the Food and Drug Administration recommended a scheduling action to control certain 7-hydroxymitragynine (also known as 7-OH) products under the Controlled Substances Act.
Kratom is illegal in Alabama, but Long said manufacturers have created synthetic versions, and by changing just one molecule, they can skirt the law and sell the products here.
Edwards has been sober for a while now, but she's not out of the woods. 'It took me months to feel even normal. I still don't have my full energy back,' she said.
Her advice to anyone thinking this might be a good idea? 'Don't do it. It's not, it's not worth it, it's not worth it.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
17 hours ago
- CTV News
Walmart recalls frozen shrimp in U.S. over potential radioactive contamination
Walmart has recalled frozen, raw shrimp sold in 13 states because federal health officials say it could have potential radioactive contamination. The U.S. Food and Drug Administration asked Walmart to pull three lots of Great Value brand frozen shrimp from stores after federal officials detected Cesium-137, a radioactive isotope, in shipping containers and a sample of breaded shrimp imported from Indonesia. ADVERTISEMENT The products could pose a 'potential health concern' for people exposed to low levels of Cesium-137 over time, FDA officials said. 'If you have recently purchased raw frozen shrimp from Walmart that matches this description, throw it away,' FDA officials said in a statement. The risk from the recalled shrimp is 'quite low,' said Donald Schaffner, a food safety expert at Rutgers University. Cesium-137 is a byproduct of nuclear reactions, including nuclear bombs, testing, reactor operations and accidents. It's widespread around the world, with trace amounts found in the environment, including soil, food and air. The level detected in the frozen breaded shrimp was far lower than FDA intervention levels. However, the agency said that avoiding potentially contaminated products could reduce exposure to low-level radiation that could lead to health problems over time. The FDA is investigating reports of Cesium-137 contamination in shipping containers and products processed by P.T. Bahari Makmur Sejati, doing business as BMS Foods of Indonesia. U.S. Customs and Border Protection officials alerted FDA that they found Cesium-137 in shipping containers sent to U.S. ports in Los Angeles, Houston, Miami and Savannah, Georgia. FDA officials collected several product samples and detected contamination in one sample of frozen breaded shrimp. The shipping containers and products were denied entry into the U.S. However, the FDA then learned that Walmart had received potentially affected products imported after the first detection, from shipments that did not trigger contamination alerts. Walmart immediately recalled the products, a company spokesperson said. They include Great Value brand frozen raw shrimp with lot codes 8005540-1, 8005538-1 and 8005539-1, all with best-by dates of March 15, 2027. The shrimp was sold in Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Missouri, Mississippi, Ohio, Oklahoma, Pennsylvania, Texas and West Virginia. Consumers should discard the products or return them to any Walmart store for refund. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content. Jonel Aleccia, The Associated Press
Globe and Mail
2 days ago
- Globe and Mail
Jupiter Neurosciences Names NBA Legend Chris Webber as Second Nugevia™ Brand Ambassador
Partnership expands momentum for launch of new longevity supplement line powered by clinical science and performance-driven innovation Jupiter, Florida, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) today announced that Chris Webber, five-time NBA All-Star and Hall of Fame inductee, has joined the Company as the second official brand ambassador for Nugevia ™, Jupiter Neurosciences' new consumer longevity supplement line. Webber, who played 15 seasons in the National Basketball Association, including standout years with the Sacramento Kings, brings his championship mindset and commitment to peak performance to the Nugevia mission. Over his career, Webber was named NBA Rookie of the Year, earned five All-NBA selections, and left an indelible mark on the game with his skill, vision, and leadership. 'Chris embodies the principles at the core of Nugevia ™: longevity, resilience, and elite performance supported by real science,' said Christer Rosén, Chairman and CEO of Jupiter Neurosciences. 'His dedication to preparation and his commitment to excellence both on and off the court make him an ideal advocate for our mission to help people look, feel, and perform their best at every stage of life.' Webber commented, 'In my playing days, staying at the top of my game took more than talent, it took discipline, recovery, and science-backed tools to keep my body and mind sharp. I'm a big believer in putting the right things in your body so you can keep giving your best, year after year. Nugevia's products aren't just another supplement, they're built on real clinical research and cutting-edge technology. Whether you're competing on the court, running a business, or just trying to keep up with your kids, Nugevia gives you that extra edge to perform at your peak.' Nugevia ™ is built on JOTROL ™, Jupiter's patented resveratrol-based micellar delivery platform that has demonstrated significantly enhanced bioavailability and underpins the Company's clinical-stage CNS therapies. The three debut formulations—GLO, MND, and PWR—are designed to support cellular resilience through intelligent stacking of synergistic ingredients, all enhanced for optimal absorption via the JOTROL ™ system. The Nugevia ™ brand reflects Jupiter's dual-path strategy, advancing clinically validated therapeutics while tapping into the rapidly growing longevity market, projected to reach $8 trillion by 2030. This consumer-facing arm is expected to create a revenue stream that supports ongoing clinical development, corporate operating costs, and enhances long-term shareholder value. A digital press kit, including high-resolution product imagery and key brand information, is available at About Jupiter Neurosciences, Inc. Jupiter Neurosciences is a clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammation and promote healthy aging. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia ™ product line. Both efforts are powered by JOTROL ™, Jupiter's proprietary, enhanced resveratrol formulation that has demonstrated significantly improved bioavailability. Nugevia brings clinical-grade science to the supplement space, supporting mental clarity, skin health, and mitochondrial function. The Company's prescription pipeline is focused broadly on CNS disorders, presently with a Phase IIa in Parkinson's disease, includeing indications such as Alzheimer's Disease, Mucopolysaccharidoses Type I, Friedreich's Ataxia, and MELAS. More information may be found on the Company's website About JOTROL Resveratrol is one of the world's most extensively researched molecules. Thorough evaluation has shown that for the compound to be effective, it requires a high C-Max (~300 ng/ml of resveratrol in plasma), achievable only with doses exceeding 3 grams using earlier resveratrol products. Poor bioavailability has been a well-documented issue with resveratrol. Doses over 2 grams have been associated with severe gastrointestinal (GI) side effects, which have prevented the compound from receiving regulatory approval for any indication. Jupiter Neurosciences (JUNS) conducted a Phase I study demonstrating that JOTROL ™ achieves over nine times higher bioavailability compared to resveratrol used in earlier clinical trials (e.g., Turner et al., MCI/Early Alzheimer's Disease trial, and Yui et al., Friedreich's Ataxia trial). The results of this Phase I study, which will be cross-referenced in all upcoming JOTROL ™ trials, were published in the Journal of Alzheimer's Disease and AAPS Open in February 2022. JUNS is now advancing JOTROL ™ toward a Phase IIa trial in Parkinson's Disease. In addition to its therapeutic applications, JOTROL ™ serves as the foundation for Jupiter's Nugevia ™ consumer supplement line. By leveraging the same clinically validated delivery technology, Nugevia ™ introduces pharmaceutical-grade bioavailability into the wellness space, offering targeted support for cognitive health, skin vitality, and cellular energy. FORWARD-LOOKING STATEMENTS Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations, including the Company's ability to generate revenues from the sale of JOTROL products to consumers through the DTC model. Investors can find many (but not all) of these statements by the use of words such as 'approximates,' 'believes,' 'hopes,' 'expects,' 'anticipates,' 'estimates,' 'projects,' 'intends,' 'plans,' 'will,' 'would,' 'should,' 'could,' 'may' or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to read the risk factors contained in the Company's final prospectus and other reports it files with the SEC before making any investment decisions regarding the Company's securities. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law.
CBC
2 days ago
- CBC
Breastfeeding could help prevent early puberty in girls and boys, South Korean study finds
Girls and boys who were exclusively breastfed during their first four to six months showed a reduced risk of early puberty, according to a large new study from South Korea that Canadian doctors say could apply here. The study, published in Monday's issue of JAMA Network Open, looked back at the diets and development of more than 300,000 children from 2007 to 2020, based on data from checkups at four to six months of age and before six years. Worldwide, puberty has increasingly begun earlier in kids. Called "central precocious puberty," it's linked to an increased risk of health problems in adulthood, like heart disease, cancer and diabetes, as well as mental health issues like depression and anxiety. The researchers believe that kids who are exclusively breastfed are less likely to develop childhood obesity, a major predisposing factor of early puberty. However, experts note that many mothers face challenges in breastfeeding, which they say should be addressed on a structural level. "The take-home message should be, for parents or to-be parents, that breastfeeding has multiple beneficial health effects for their children," said Dr. Sonia Anand, associate vice-president of global health at McMaster University, who was not involved in the study. "And the second message is it is not always easy to do." Long-term benefits of breastfeeding About 46 per cent of the babies in the South Korean study were exclusively breastfed, more than a third had formula and nearly 20 per cent had both. "The idea is that breastfed kids are less likely to have extra weight and that's the mechanism whereby they're more protected from developing early puberty," said Dr. Kaberi Dasgupta, a professor of medicine and physician scientist at the McGill University Health Centre, who also was not involved in the study. Boys who were fed just formula had a 16 per cent increased risk of early puberty compared with their peers who were only fed breast milk, the researchers found. For exclusively formula-fed girls, the association jumped to 60 per cent. For mixed-fed boys, it was 14 per cent higher, compared with 45 per cent for girls. The researchers noted some caveats to their study. The participants self-reported how long they breastfed their children, for example. It also couldn't include genetic factors like maternal age of puberty. The early part of life is a key time, as that's when a lot of disease risk is set, wrote doctors Lin Yang and Shengxu Li. Though they weren't involved in the study, they wrote an accompanying journal commentary. "Disease starts early, so should its prevention," they said. Dasgupta says there's no reason to think the findings would be different in Canada. Preventing early puberty can also help kids in other ways, she adds. "The earlier your puberty, the shorter you may become," she said. "There's also the stigma around having early signs of being an adult when you're still a kid. Other kids may tease you." Supporting mothers instead of shaming Yang and the researchers say that instead of putting pressure on new moms, a society-wide approach is important. That includes stronger parental leave policies, workplace accommodations like a private space to breastfeed and lactation support services. "I think policy support, raised awareness, as well as creating the environment for women to be able to [breastfeed] is very important," Yang told CBC News. Sleep patterns, physical activity levels and screen time could also be increasing childhood obesity and early puberty rates, Yang and Li wrote in their commentary, as well as environmental pollutants like endocrine disruptors, though she acknowledged there isn't good data on that. In Canada, about 91 per cent of parents start out breastfeeding. About 38 per cent of parents breastfed exclusively for at least six months, Statistics Canada reported in 2024. Of those who stopped before six months, reasons included not having enough breast milk, finding breastfeeding difficult and the child weaning themself off of it. "I think the wrong takeaway and the wrong approach is to shame mothers who try to breastfeed but can't continue," Anand said. Breastfeeding is one factor among many that can influence weight gain in kids. Lifestyle choices like limiting fast food and cooking with more vegetables and lean proteins can also help prevent childhood obesity, doctors say. While the South Korean study doesn't prove that formula feeding causes early puberty, the researchers had a robust data set and the associations are plausible, she said. Anand's own research demonstrated early breastfeeding and for at least six months was associated with lower levels of excess body fat in children at age three. She says she'd like to see other large studies show similar findings to the South Korean to nail down cause and effect. Studies looking at how genes are tied to precocious puberty could also help, she said.
